Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-05-17 00:00:00 ET · period of report 2024-05-17 · accession 0001883850-24-000025 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-05-17 | 2024-05-17 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Bd. Co-COB, Dir | S - Sale | $979.23 | -22.8K | 466.9K | -5% | -$22.36M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-17 | S | D | 22,687 | $979.22 | 467,020 | D | — | — | (F2) Represents volume-weighted average price of sales of 22,687 shares of Company stock on May 17, 2024 at prices ranging from $979.00 to $979.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price. |
| 2 | Common | Common Stock | 2024-05-17 | S | D | 143 | $980.07 | 466,877 | D | — | — | (F3) Represents volume-weighted average price of sales of 143 shares of Company stock on May 17, 2024 at prices ranging from $980.01 to $980.20. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2024 at each separate price. |